CY1114804T1 - Νεες ενωσεις 951: ενα διφαινυλοξυπροπανοϊκο οξυ ως ρυθμιστης crth2 και ενδιαμεσες ενωσεις - Google Patents

Νεες ενωσεις 951: ενα διφαινυλοξυπροπανοϊκο οξυ ως ρυθμιστης crth2 και ενδιαμεσες ενωσεις

Info

Publication number
CY1114804T1
CY1114804T1 CY20141100033T CY141100033T CY1114804T1 CY 1114804 T1 CY1114804 T1 CY 1114804T1 CY 20141100033 T CY20141100033 T CY 20141100033T CY 141100033 T CY141100033 T CY 141100033T CY 1114804 T1 CY1114804 T1 CY 1114804T1
Authority
CY
Cyprus
Prior art keywords
differenylyxypopanic
crth2
regulator
acid
intermediate compounds
Prior art date
Application number
CY20141100033T
Other languages
Greek (el)
English (en)
Inventor
Roger Victor Bonnert
Timothy Jon Luker
Anil Patel
Aaron Rigby
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39942682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114804(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1114804T1 publication Critical patent/CY1114804T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
CY20141100033T 2007-07-05 2014-01-15 Νεες ενωσεις 951: ενα διφαινυλοξυπροπανοϊκο οξυ ως ρυθμιστης crth2 και ενδιαμεσες ενωσεις CY1114804T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94801207P 2007-07-05 2007-07-05
EP08776164.9A EP2173730B1 (en) 2007-07-05 2008-07-01 Novel compounds 951: a biphenyloxypropanoic acid as crth2 modulator and intermediates

Publications (1)

Publication Number Publication Date
CY1114804T1 true CY1114804T1 (el) 2016-12-14

Family

ID=39942682

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100033T CY1114804T1 (el) 2007-07-05 2014-01-15 Νεες ενωσεις 951: ενα διφαινυλοξυπροπανοϊκο οξυ ως ρυθμιστης crth2 και ενδιαμεσες ενωσεις

Country Status (29)

Country Link
US (1) US8507544B2 (OSRAM)
EP (1) EP2173730B1 (OSRAM)
JP (1) JP5368438B2 (OSRAM)
KR (1) KR20100039326A (OSRAM)
CN (1) CN101796042B (OSRAM)
AR (1) AR067461A1 (OSRAM)
AU (1) AU2008272690B2 (OSRAM)
BR (1) BRPI0813992A2 (OSRAM)
CA (1) CA2691615A1 (OSRAM)
CL (1) CL2008001982A1 (OSRAM)
CO (1) CO6270211A2 (OSRAM)
CY (1) CY1114804T1 (OSRAM)
DK (1) DK2173730T3 (OSRAM)
EC (1) ECSP109848A (OSRAM)
ES (1) ES2442523T3 (OSRAM)
HR (1) HRP20140004T1 (OSRAM)
MY (1) MY153957A (OSRAM)
NZ (1) NZ582192A (OSRAM)
PE (2) PE20121515A1 (OSRAM)
PL (1) PL2173730T3 (OSRAM)
PT (1) PT2173730E (OSRAM)
RS (1) RS53129B (OSRAM)
SA (1) SA08290406B1 (OSRAM)
SI (1) SI2173730T1 (OSRAM)
TW (1) TWI453017B (OSRAM)
UA (1) UA100983C2 (OSRAM)
UY (1) UY31208A1 (OSRAM)
WO (1) WO2009004379A1 (OSRAM)
ZA (1) ZA200909226B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
JP2009514935A (ja) * 2005-11-05 2009-04-09 アストラゼネカ・アクチエボラーグ 新規化合物
US20080293775A1 (en) * 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
WO2009099902A1 (en) 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
SG10201404662YA (en) 2009-08-05 2014-10-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
EP2590944B1 (en) 2010-07-05 2015-09-30 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2794563B1 (en) 2011-12-21 2017-02-22 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
KR101538846B1 (ko) 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278524A (en) 1962-03-13 1966-10-11 Beecham Group Ltd Penicillins and their production
CH432119A (de) 1963-02-22 1967-03-15 Geigy Ag J R Verwendung von Halogen-o-hydroxy-diphenyläthern als antimikrobielle Mittel
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
DD113545A5 (OSRAM) 1973-03-30 1975-06-12
JPS5239888B2 (OSRAM) 1973-05-28 1977-10-07
CH582476A5 (OSRAM) 1973-10-29 1976-12-15 Ciba Geigy Ag
GB1585963A (en) 1976-10-14 1981-03-11 Lilly Industries Ltd Aryl sulphur compounds
JPS5951943B2 (ja) 1978-08-21 1984-12-17 キツセイ薬品工業株式会社 新規なイミダゾ−ル誘導体
GB2041363B (en) 1979-01-19 1982-10-06 Pfizer Ltd N-benzyl-imidazoles
US4670566A (en) 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4486593A (en) 1983-01-19 1984-12-04 The Upjohn Company 2-,3-, or 4-Pyridinylmethylamino arylic acids as thromboxane A2 synthetase and 5-lipoxygenase inhibitors
US5006542A (en) 1988-10-31 1991-04-09 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, derivatives thereof, compositions containing same and method of use
US5145790A (en) 1990-05-04 1992-09-08 Abbott Laboratories Reagents and method for detecting polychlorinated biphenyls
EP0540165A1 (en) 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
WO1993012086A1 (fr) 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Derive d'arylamide
CA2090283A1 (en) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
ES2156120T3 (es) 1992-12-08 2001-06-16 Ss Pharmaceutical Co Derivados arilamidicos.
JPH06313995A (ja) 1993-04-28 1994-11-08 Hodogaya Chem Co Ltd 静電荷像現像用トナー
JPH07140725A (ja) 1993-06-25 1995-06-02 Hodogaya Chem Co Ltd 負帯電性トナー用摩擦帯電付与部材
BR9610207A (pt) 1995-08-28 1999-02-02 American Home Prod Acidos fenóxi acéticos como inibidores da aldose redutase e agentes anti-hiperglicêmicos
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CA2219269A1 (en) 1996-10-29 1998-04-29 Novartis Ag Novel herbicides
FR2763588B1 (fr) 1997-05-23 1999-07-09 Cird Galderma Composes triaromatiques, compositions les contenant et utilisations
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
WO1999014194A1 (en) 1997-09-12 1999-03-25 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
WO1999019291A1 (en) 1997-10-14 1999-04-22 Asahi Kasei Kogyo Kabushiki Kaisha Biphenyl-5-alkanoic acid derivatives and use thereof
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
JP3486408B2 (ja) 1999-08-23 2004-01-13 株式会社ビー・エム・エル 物質のヒトプロスタグランジンｄ２受容体に対する性質の同定方法
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2003531194A (ja) 2000-04-24 2003-10-21 メルク フロスト カナダ アンド カンパニー プロスタグランジンｅ阻害薬としてフェニルおよびビアリール誘導体を用いる治療方法および該方法に有用な化合物
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
HRP20030027A2 (en) 2000-06-28 2004-02-29 Teva Pharma Carvedilol
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
JP2005505506A (ja) 2001-06-12 2005-02-24 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用な大環状分子
PL373410A1 (en) 2002-02-01 2005-08-22 F.Hoffman-La Roche Ag Substituted indoles as alpha-1 agonists
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003068744A1 (en) 2002-02-18 2003-08-21 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
CA2479338A1 (en) 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
EP1585511B1 (en) 2002-12-20 2013-01-23 Amgen Inc. Asthma and allergic inflammation modulators
US7414063B2 (en) 2003-03-28 2008-08-19 Eli Lilly And Company Inhibitors of Akt (protein kinase B)
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
JP2008500991A (ja) 2004-05-29 2008-01-17 ７ティーエム ファーマ エイ／エス 医学的使用のためのｃｒｔｈ２レセプターリガンド
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) * 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
JP2009514935A (ja) 2005-11-05 2009-04-09 アストラゼネカ・アクチエボラーグ 新規化合物
US20080293775A1 (en) 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты

Also Published As

Publication number Publication date
PL2173730T3 (pl) 2014-03-31
DK2173730T3 (da) 2014-01-20
HRP20140004T1 (hr) 2014-02-14
PE20121515A1 (es) 2012-12-16
JP5368438B2 (ja) 2013-12-18
CO6270211A2 (es) 2011-04-20
US20090012151A1 (en) 2009-01-08
EP2173730A1 (en) 2010-04-14
CN101796042B (zh) 2013-05-08
SA08290406B1 (ar) 2013-04-02
UA100983C2 (ru) 2013-02-25
AU2008272690A1 (en) 2009-01-08
BRPI0813992A2 (pt) 2017-05-09
MY153957A (en) 2015-04-30
PT2173730E (pt) 2014-01-16
NZ582192A (en) 2012-01-12
US8507544B2 (en) 2013-08-13
RU2010101278A (ru) 2011-08-10
CA2691615A1 (en) 2009-01-08
AR067461A1 (es) 2009-10-14
ZA200909226B (en) 2011-05-25
KR20100039326A (ko) 2010-04-15
PE20090475A1 (es) 2009-05-24
CN101796042A (zh) 2010-08-04
WO2009004379A1 (en) 2009-01-08
UY31208A1 (es) 2009-03-02
JP2010532340A (ja) 2010-10-07
ECSP109848A (es) 2010-02-26
CL2008001982A1 (es) 2009-07-17
EP2173730B1 (en) 2013-11-06
TW200913990A (en) 2009-04-01
ES2442523T3 (es) 2014-02-12
SI2173730T1 (sl) 2014-02-28
HK1143140A1 (en) 2010-12-24
AU2008272690B2 (en) 2012-03-22
RS53129B (sr) 2014-06-30
TWI453017B (zh) 2014-09-21

Similar Documents

Publication Publication Date Title
CY1114804T1 (el) Νεες ενωσεις 951: ενα διφαινυλοξυπροπανοϊκο οξυ ως ρυθμιστης crth2 και ενδιαμεσες ενωσεις
CY1111469T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ 3-ΦΑΙΝΥΛΘΕΙΟ-1Η-ΙΝΔΟΛΗ-1-ΟΞΙΚΟΥ ΟΞΕΟΣ ΩΣ ΡΥΘΜΙΣΤΕΣ ΤΗΣ ΔΡΑΣΗΣ ΤΟΥ ΥΠΟΔΟΧΕΑ CRTh2
CY1115873T1 (el) Νεοι ανταγωνιστες υποδοχεα ccr2 και χρησεις αυτων
CY1110812T1 (el) Παραγωγα διφαινυλοξυοξικου οξεος για τη θεραπεια αναπνευστικων διαταραχων
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
UY28482A1 (es) Nuevos compuestos
NO20084005L (no) Aminderivater
BR112015029970A2 (pt) inibidores de cinase
SE0202241D0 (sv) Novel Compounds
CY1115940T1 (el) Παραγωγα υποκατεστημενου φαινυλαλκανοϊκου οξεος και η χρηση τους για τη θεραπευτικη αντιμετωπιση αναπνευστικων ασθενειων
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
EA201100423A1 (ru) Новые бензамиды, их получение и их применение в качестве лекарственных средств
CL2007003826A1 (es) Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion.
NO20045589L (no) Nye forbindelser
MY151172A (en) Pyrimidine amide compounds as pgds inhibitors
EA201100942A1 (ru) Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
ECSP088628A (es) Moduladores de receptores cannabinoides
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
CY1112520T1 (el) Βενζυλαμινες, μια διαδικασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδεις παραγοντες
AR072229A1 (es) Derivados de n- oxido pirazina sustituidos
CY1112255T1 (el) Ενωσεις οι οποιες περιεχουν γουανιδινη που ειναι χρησιμες ως ανταγωνιστες του μουσκαρινικου υποδοχεα
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
EA201200855A1 (ru) Модуляторы crth2